Ensign Peak Advisors
TRVI icon

Ensign Peak Advisors’s Trevi Therapeutics TRVI Stock Holding History

Ensign Peak Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.39M Sell
396,173
-68,573
-15% -$997K 0.01% 489
2026
Q1 		$5.54M Buy
+464,746
New +$5.2M 0.01% 511

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Ensign Peak Advisors's TRVI Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Trevi Therapeutics (TRVI) stake by 15% in Q2 2026, selling an estimated $997K and leaving 396,173 shares worth $7.39M. The position accounts for 0.01% of the portfolio, ranked #489.

Ensign Peak Advisors first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Ensign Peak Advisors held 396,173 shares of Trevi Therapeutics worth $7.39M as of Q2 2026.
  • Ensign Peak Advisors sold 68,573 Trevi Therapeutics shares in Q2 2026, an estimated $997K.
  • Trevi Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #489 holding.
  • Ensign Peak Advisors first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.